Core Insights - Rigel Pharmaceuticals reported a significant increase in net product sales for 2025, reaching $232 million, which is a 60% increase compared to 2024, driven by increased demand and favorable dynamics in patient affordability [1][6][20] - The company has transitioned from a single-product focus to marketing three products: TAVALISSE, REZLIDHIA, and GAVRETO, with plans to pursue late-stage in-licensing and acquisition opportunities [2][3][20] - Rigel's financial performance was bolstered by a non-cash deferred tax benefit, resulting in a net income of $367 million for 2025, compared to $17.5 million in 2024 [4][19][24] Financial Performance - For Q4 2025, Rigel reported total revenue of $69.8 million, including $65.4 million in net product sales and $4.4 million in collaboration revenues [16] - The company guided for 2026 revenue between $275 million and $290 million, with expectations of positive net income while funding clinical development programs [20][21] - Total costs and expenses for 2025 were $168.8 million, an increase from $155.1 million in 2024, with R&D costs rising due to clinical activities for R289 and olutasidenib [17][24] Product Performance - TAVALISSE generated $45.6 million in sales for Q4 2025, up 47% year-over-year, while GAVRETO and REZLIDHIA contributed $10.2 million and $9.6 million, respectively [9][6] - R289, the lead pipeline candidate, showed early efficacy in lower-risk myelodysplastic syndromes (MDS), with 33% of evaluable patients achieving transfusion independence [5][13][10] - The company is advancing R289 through a randomized dose-expansion study, with expectations for Phase 2 dose decision data by the end of the year [14][15] Strategic Outlook - Rigel aims to build on the momentum of its marketed products while selectively pursuing late-stage business development opportunities in hematology and oncology [2][21] - The company is focusing on NDA-ready or under-review assets that could be launched within the next three years [21] - Rigel's strategy includes leveraging partnerships for international product availability and regulatory submissions in new markets [8]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported net product sales of $65.4 million, a 41% increase year-over-year, with TAVALISSE generating $45.6 million, a 47% increase, GAVRETO at $10.2 million, a 27% increase, and REZLIDHIA at $9.6 million, a 29% increase [12][15][32] - Full year 2025 net product sales reached $232 million, an increase of $87 million or 60% compared to 2024, driven by increased demand and favorable gross to net dynamics [13][38] - The company reported net income of $268.1 million for Q4 2025, compared to $14.3 million for the same period in 2024, and a full year net income of $367 million, compared to $17.5 million in 2024 [35][38] Business Line Data and Key Metrics Changes - TAVALISSE, the cornerstone product, achieved record quarterly sales of $45.6 million, while GAVRETO and REZLIDHIA contributed $10.2 million and $9.6 million respectively [15][32] - The company has expanded its portfolio from a single product in 2020 to three commercial products by the end of 2025, indicating significant growth in its business lines [6][7] Market Data and Key Metrics Changes - The company anticipates a compound annual growth rate of approximately 35% in net product sales from 2022 to 2026, with guidance for 2026 net product sales between $255 million and $265 million [9][38] - The market for TAVALISSE is estimated to have over 14,000 patients in the second-line and later setting, indicating a substantial opportunity for growth [46] Company Strategy and Development Direction - The company’s strategy focuses on four core objectives: growing the commercial business, expanding the portfolio through in-licensing or acquisition, advancing the clinical development pipeline, and maintaining financial discipline [5][9] - The company plans to continue advancing R289 in lower risk MDS and explore additional indications, which are seen as large commercial opportunities [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential of R289 and the overall commercial portfolio, highlighting the importance of maintaining momentum from 2025 into 2026 [40] - The company acknowledged the challenges of sustaining high growth rates but remains committed to achieving double-digit growth in 2026 [70][71] Other Important Information - The company has a strong cash position, ending 2025 with cash equivalents and short-term investments of $155 million, up from $77.3 million at the end of 2024 [38] - The company has received Fast Track designation and Orphan Drug Designation for R289 from the FDA, indicating regulatory support for its development [23] Q&A Session Summary Question: What are the growth drivers for TAVALISSE and GAVRETO? - Management noted that TAVALISSE's growth was aided by a one-time favorable effect from increased patient affordability, and future growth will focus on new patient starts [44][46] Question: What is the rationale for exploring R289 in earlier line populations? - Management indicated that moving R289 into earlier lines of therapy could yield better activity compared to existing treatments, which have limitations [59][61] Question: How is enrollment in the R289 dose expansion phase progressing? - Management confirmed that enrollment is on track and that follow-up for evaluating red cell transfusion independence will require at least 16 weeks of treatment [67]

Financial Data and Key Metrics Changes - For Q4 2025, Rigel reported net product sales of $65.4 million, a 41% increase year-over-year, with TAVALISSE contributing $45.6 million (up 47%), GAVRETO at $10.2 million (up 27%), and REZLIDHIA at $9.6 million (up 29%) [32][35][36] - Full year 2025 net product sales reached $232 million, an increase of $87 million or 60% compared to 2024, driven by increased demand and favorable gross to net dynamics [12][13][37] - The company reported net income of $367 million for the full year 2025, compared to $17.5 million in 2024, reflecting a significant improvement in profitability [35][36] Business Line Data and Key Metrics Changes - TAVALISSE, the cornerstone product, achieved record quarterly sales of $45.6 million in Q4 2025, marking a 47% increase from Q4 2024 [15][32] - GAVRETO, launched in mid-2024, generated $10.2 million in Q4 2025, showing a 27% increase year-over-year, indicating successful integration into Rigel's portfolio [15][16] - REZLIDHIA, since its in-licensing in 2022, has grown to nearly $10 million in quarterly sales, with Q4 2025 sales of $9.6 million, a 29% increase compared to the prior year [16][18] Market Data and Key Metrics Changes - Rigel's net product sales growth reflects strong commercial execution and successful portfolio expansion, achieving a compound annual growth rate of approximately 35% since 2022 [9] - The company is expanding access to TAVALISSE in global markets, with ongoing regulatory approvals in various countries [17] Company Strategy and Development Direction - Rigel's growth strategy focuses on four core objectives: growing the commercial business, expanding the portfolio through in-licensing or acquisition, advancing the clinical development pipeline, and maintaining financial discipline [5][9] - The company aims to build on the commercial momentum of its three products while pursuing late-stage in-licensing opportunities and advancing R289 in lower risk MDS [9][10] - R289, a dual IRAK1 and IRAK4 inhibitor, is positioned as a potential treatment for lower risk MDS, with promising preliminary efficacy data [8][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, highlighting the transformational growth since 2020 and the expectation of continued double-digit growth in 2026 [39] - The company anticipates total revenue in the range of $275 million to $290 million for 2026, with a focus on maintaining profitability while funding clinical development programs [37][39] Other Important Information - Rigel has a proven track record in business development, successfully integrating acquired products into its portfolio with limited integration costs [10] - The company has received Fast Track and Orphan Drug Designation for R289 from the FDA, indicating a favorable regulatory pathway [23] Q&A Session Summary Question: What are the growth drivers for TAVALISSE and GAVRETO? - Management noted that TAVALISSE's growth was aided by a one-time favorable effect from increased patient affordability, and future growth will focus on new patient starts [41][44] - For GAVRETO, management highlighted targeted efforts to continue growth, leveraging the product's established presence in the market [46] Question: What is the rationale for exploring R289 in earlier line populations? - Management explained that moving R289 into earlier lines of therapy could yield better activity compared to existing treatments, which have shown limited response rates [58][61] Question: What is the status of enrollment for R289's dose expansion phase? - Enrollment is progressing well, with plans to select the recommended phase II dose in the second half of the year [66] Question: Why is the 2026 net product sales guidance conservative? - Management indicated that while they expect double-digit growth, the absence of one-time favorable effects from the previous year and the higher sales base present challenges [67][70] Question: Are there plans to expand the sales force? - Management stated that they are not looking to expand the sales organization at this time but are focused on maximizing the effectiveness of the current team [75][77]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported net product sales of $65.4 million, a 41% increase year-over-year, with TAVALISSE generating $45.6 million (up 47%), GAVRETO at $10.2 million (up 27%), and REZLIDHIA at $9.6 million (up 29%) [30][12][14] - Full year 2025 net product sales reached $232 million, an increase of $87 million or 60% compared to 2024, driven by increased demand and favorable gross to net dynamics [12][30] - The company reported net income of $268.1 million for Q4 2025, compared to $14.3 million for the same period in 2024, and a full year net income of $367 million, up from $17.5 million in 2024 [33][34] Business Line Data and Key Metrics Changes - TAVALISSE, the cornerstone product, achieved record quarterly sales of $45.6 million, while GAVRETO and REZLIDHIA contributed $10.2 million and $9.6 million respectively [13][14] - The company has expanded its portfolio from a single product in 2020 to three commercial products by the end of 2025, indicating successful portfolio growth [5][6] Market Data and Key Metrics Changes - The company has seen strong net product sales growth since emerging from the COVID pandemic, with a compound annual growth rate of approximately 35% since 2022 [8] - The market for TAVALISSE includes over 14,000 patients in the second-line and later setting, indicating significant growth potential [44] Company Strategy and Development Direction - The company’s strategy focuses on four core objectives: growing the commercial business, expanding the portfolio through in-licensing or acquisition, advancing the clinical development pipeline, and maintaining financial discipline [4][7] - The company plans to continue advancing R289 in lower risk MDS and explore additional indications, which represent large commercial opportunities [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, expecting total revenue in 2026 to be in the range of $275 million to $290 million, with net product sales guidance of $255 million to $265 million [35] - The company aims to maintain profitability while funding existing and new clinical development programs, reflecting a strong financial position [36][37] Other Important Information - The company has a promising clinical profile for R289, which has received Fast Track and Orphan Drug Designation from the FDA, indicating a favorable regulatory pathway [22] - The company is actively pursuing late-stage assets that are NDA-ready or already commercially available to enhance its portfolio [10] Q&A Session Summary Question: What are the growth drivers for TAVALISSE and GAVRETO? - Management noted that TAVALISSE's growth was aided by a one-time favorable effect from increased patient affordability, and future growth will focus on new patient starts [42][44] - For GAVRETO, management highlighted targeted efforts to continue growth, leveraging the full year of sales compared to the previous year [45] Question: What is the rationale for exploring R289 in earlier line populations? - Management explained that moving R289 into earlier lines of therapy could yield better activity compared to the heavily pretreated population currently being studied [58] Question: What are the challenges in patient enrollment for R289? - Management confirmed that enrollment is progressing well and that patients need to be treated for at least 16 weeks to evaluate red cell transfusion independence [66] Question: Why is the 2026 sales guidance conservative? - Management indicated that while they expect double-digit growth, the absence of one-time favorable effects from the previous year and the higher sales base make it a challenging outlook [67][70] Question: Are there plans to expand the sales force? - Management stated that they are not looking to expand the sales organization at this time but are focused on maximizing the impact of the current team [78]

Q4 & FY 2025 Financial Results Presentation March 3, 2026 1 Forward Looking Statements Rigel Participants Raul Rodriguez President & Chief Executive Officer Ray Furey, J.D. Executive Vice President, General Counsel & Corporate Secretary This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") relating to, among other things, continued development and expansion of our business, projected financial performance including sales an ...

Core Insights - Rigel Pharmaceuticals reported strong financial results for Q4 and full year 2025, with record net product sales and total revenues, setting a positive outlook for 2026 [1][2] Financial Performance - Total revenues for Q4 2025 were approximately $69.8 million, including net product sales of $65.4 million, a 41% increase from Q4 2024 [2][4] - For the full year 2025, total revenues reached approximately $294.3 million, with net product sales of $232.0 million, reflecting a 60% increase from 2024 [2][4] - Rigel reported a net income of $268.1 million for Q4 2025 and $367.0 million for the full year, significantly up from $14.3 million in Q4 2024 [2][4] Product Sales - Net product sales for TAVALISSE® were $45.6 million in Q4 2025, a 47% increase from Q4 2024, while GAVRETO® and REZLIDHIA® saw sales of $10.2 million and $9.6 million respectively, marking increases of 27% and 29% [2][4] - For the full year 2025, TAVALISSE® sales were $158.8 million, GAVRETO® sales were $42.1 million (up 146%), and REZLIDHIA® sales were $31.0 million (up 35%) compared to 2024 [2][4] Clinical Development - Enrollment in the Phase 1b study of R289 for lower-risk MDS is ongoing, with completion expected in the second half of 2026 [1][2] - The FDA approved a supplemental New Drug Application for GAVRETO, adding a boxed warning regarding serious infections [1][2] - Rigel presented data at the ASCO-GI symposium showing a 67% overall response rate for pralsetinib in patients with RET fusion-positive solid tumors [1][2] 2026 Outlook - Rigel anticipates total revenues of approximately $275 to $290 million for 2026, including net product sales of $255 to $265 million and positive net income [1][2]

Summary of Rigel Pharmaceuticals FY Conference Call Company Overview - **Company**: Rigel Pharmaceuticals (NasdaqGS:RIGL) - **Date of Conference**: January 14, 2026 - **Speaker**: Raul Rodriguez, CEO and President Key Industry and Company Insights Strategic Objectives - Rigel's strategic plan includes four objectives: 1. Grow the commercial business 2. In-license and add products to the commercial portfolio 3. Advance the product pipeline in the clinic 4. Maintain financial discipline [2][4][41] Historical Growth - In 2020, Rigel was a one-product company with Tavalisse for adult chronic ITP. - By 2025, the company expanded to three commercial products: Tavalisse, Rezlidhia, and Gavreto, with four different indications [3][4]. Financial Performance - Rigel became profitable in Q3 2024, generating $100 million in cash since then [4]. - The company reported a 35% sales growth from 2022, projecting total revenue of $275-$290 million for the year, with product revenue between $255-$265 million [6][42]. Product Performance Tavalisse - Tavalisse sales grew by 47%, reaching $45 million, with a significant patient population of approximately 24,000 in the U.S. [7][9]. - The product is used primarily in patients who have failed first-line steroid treatments [10][11]. - The Inflation Reduction Act positively impacted patient retention on Tavalisse, reducing dropout rates due to affordability issues [12][13]. Rezlidhia - Rezlidhia targets adult patients with relapsed or refractory AML with an IDH1 mutation, addressing a significant unmet need [14][15]. - The product achieved a CR/CRH rate of 35% with a durability of response lasting 25 months [16]. Gavreto - Gavreto is indicated for non-small cell lung cancer and thyroid cancer with RET fusion-positive mutations, showing good sales growth from $7 million to over $10 million per quarter [17][18]. Pipeline Development R289 (IRAK1 and 4 Inhibitor) - R289 is being studied in low-risk MDS, with potential for significant market opportunities estimated in the multi-hundred million to billion-dollar range [6][29]. - The product has received fast track and orphan designation from the FDA, with ongoing studies to evaluate its efficacy in treating low-risk MDS [25][39]. Future Plans - Rigel aims to launch additional products in the Heme-Onc space by 2026-2028, focusing on late-stage assets with registrational data [20][21]. - The company is exploring other indications for R289, leveraging its unique mechanism of action in inflammatory modulation [43][44]. Financial Discipline - Rigel has maintained a strong cash position, doubling its cash reserves to $154 million in 2025, allowing for further investment in pipeline development [41]. - The company emphasizes maintaining low operational expenses while growing revenue, achieving a balance that supports profitability [40]. Conclusion - Rigel Pharmaceuticals is positioned for continued growth with a diversified product portfolio and a promising pipeline. The company is focused on expanding its commercial business, advancing its development pipeline, and maintaining financial discipline to support future initiatives [41][42].

Core Insights - Rigel Pharmaceuticals reported strong financial performance in 2025, with record net product sales and significant cash generation, anticipating continued growth in 2026 [2][4][11] Financial Performance - Preliminary total revenue for Q4 2025 is expected to be approximately $69.8 million, a 21% increase from $57.6 million in Q4 2024 [5] - For the full year 2025, total revenue is projected to be $294.3 million, up from $179.3 million in 2024, representing a growth of 64% [5] - Net product sales for 2025 are expected to be $232.0 million, a 60% increase compared to 2024 [7] Product Sales Breakdown - Q4 2025 net product sales include: - TAVALISSE: $45.6 million, up from $31.0 million in Q4 2024 - GAVRETO: $10.2 million, up from $8.1 million in Q4 2024 - REZLIDHIA: $9.6 million, up from $7.4 million in Q4 2024 [5] Clinical Development - Rigel is advancing its Phase 1b clinical study of R289 for lower-risk MDS, with preliminary data indicating 33% of patients achieved red blood cell transfusion independence [9] - The company plans to complete enrollment in the dose expansion phase of the R289 study by the second half of 2026 and share preliminary results by the end of 2026 [9][11] 2026 Outlook - Rigel anticipates total revenue for 2026 to be between $275 million and $290 million, with net product sales projected at $255 million to $265 million [11] - The company expects to report positive net income for the full year 2026 while funding existing and new clinical development programs [11]

Core Insights - Rigel Pharmaceuticals announced updated data from its ongoing Phase 1b study of R289, an oral prodrug of R835, targeting relapsed or refractory lower-risk myelodysplastic syndrome (MDS) [1][2] - The study results were presented at the 67th American Society of Hematology Annual Meeting, highlighting the potential of R289 as a treatment option for patients with transfusion-dependent lower-risk MDS [1][2] Study Overview - The Phase 1b study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory lower-risk MDS [2] - Enrollment in the dose escalation phase was completed in July 2025, with the dose expansion phase starting in October 2025, involving up to 40 patients [2] Key Data Highlights - As of October 28, 2025, 33 patients were enrolled, with a median age of 75 and a median of 3 prior therapies [4] - R289 was generally well tolerated, with 33% of evaluable transfusion-dependent patients achieving durable red blood cell transfusion independence (RBC-TI) [3][4] - The most common treatment-emergent adverse events included diarrhea (30%), constipation (27%), and fatigue (27%) [4] Efficacy Results - Among evaluable transfusion-dependent patients, 6 out of 18 (33%) achieved RBC-TI lasting more than 8 weeks, with a median time to onset of 1.9 months [4] - Peak hemoglobin increases ranged from 2.9 to 6.1 g/dL compared to baseline in patients achieving RBC-TI [4] Regulatory Designations - R289 has received Orphan Drug designation and Fast Track designation from the FDA for the treatment of previously-treated transfusion-dependent lower-risk MDS [5]

Financial Performance & Guidance - Q3 2025 net product sales grew to $64.1 million, a 65% increase compared to Q3 2024[10, 158] - Rigel increased its 2025 net product sales guidance to $225 million - $230 million, up from $210 million - $220 million[12] - Rigel anticipates 2025 total revenue of ~$285 million to $290 million[162] - Cash, cash equivalents & short-term investments as of September 30, 2025, was $137.1 million compared to $77.3 million as of December 31, 2024[162] Product Performance - TAVALISSE Q3 2025 net product sales reached $44.7 million, a 70% increase compared to Q3 2024[16] - GAVRETO Q3 2025 net product sales reached $11.1 million, a 56% increase compared to Q3 2024[16] - REZLIDHIA Q3 2025 net product sales reached $8.3 million, a 50% increase compared to Q3 2024[16] R289 Clinical Development - In a Phase 1b study in R/R lower-risk MDS, 33% (6/18) of evaluable transfusion-dependent patients receiving ≥500 mg QD achieved RBC-TI >8 weeks[124, 131] - The median duration of RBC-TI was 22.9 weeks (9 - 104.3)[124] Strategic Collaborations - Contract revenues from collaborations were $5.4 million in Q3 2025[158]